Evidence map›Paper›PMID 39599798›Full record

ArticleViruses2024

Emergence of a New Pathogen: A Retrospective Study of HPeV-5 Central Nervous System Disease in Alberta, Canada.

Grace George, Lea Restivo, Dolores Freire Jijon, Joan L Robinson, Kevin Fonseca, Kanti Pabbaraju, Xiaoli Dong, Raymond Tellier, Tarah Lynch, Joseph V Vayalumkal

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Grace GeorgeSchool of Public Health, University of Alberta, Edmonton, AB T6G 1C9, Canada.
Lea RestivoDepartment of Pediatrics, Alberta Children's Hospital, University of Calgary, Calgary, AB T3B 6A8, Canada.
Dolores Freire JijonDepartment of Pediatrics, Stollery Children's Hospital, University of Alberta, Edmonton, AB T6G 2B7, Canada.ORCID 0000-0002-7579-4584
Joan L RobinsonDepartment of Pediatrics, Stollery Children's Hospital, University of Alberta, Edmonton, AB T6G 2B7, Canada.ORCID 0000-0001-9831-5681
Kevin FonsecaAlberta Precision Laboratories, Provincial Laboratory for Public Health, Calgary, AB T2N 4W4, Canada.
Kanti PabbarajuAlberta Precision Laboratories, Provincial Laboratory for Public Health, Calgary, AB T2N 4W4, Canada.ORCID 0000-0002-7409-579X
Xiaoli DongAlberta Precision Laboratories, Provincial Laboratory for Public Health, Calgary, AB T2N 4W4, Canada.
Raymond TellierDepartment of Medicine, McGill University, Montreal, QC H4A 3J1, Canada.
Tarah LynchAlberta Precision Laboratories, Provincial Laboratory for Public Health, Calgary, AB T2N 4W4, Canada.ORCID 0000-0001-5438-7114
Joseph V VayalumkalDepartment of Pediatrics, Alberta Children's Hospital, University of Calgary, Calgary, AB T3B 6A8, Canada.

Funding

Department of Pediatrics, University of Calgary n/a 0000University of Calgary n/a 0000
6 · The paper itself

Abstract

Human parechoviruses (HPeVs) are known to cause meningo-encephalitis among neonates and infants. We aimed to describe the epidemiology of HPeVs causing central nervous system infections in Alberta from 2014 to 2019 with comparison of known HPeV-3 and emerging HPeV-5. Genomic analysis was completed on a subset of HPeV-5 strains to understand genetic relatedness to other known strains. All cerebrospinal fluid (CSF) samples in Alberta with detection of HPeVs were identified and a case review of medical records was conducted, retrospectively, to gather demographic and clinical details. Descriptive and analytic statistics were used to describe and compare the characteristics of cases affected by HPeV-3 with HPeV-5. Genome amplification was completed on six HPeV-5 samples. During the study period, 18,882 CSF samples were tested; 56 were positive for HPeV-3 or HPeV-5, and 52 patients were included in this study (40 HPeV-3 cases and 12 HPeV-5). A total of 40% of cases occurred in 2016, and 64% of infections occurred in the months of August to October. The mean age of cases was 18 days for HPeV-5 compared with 26 days for HPeV-3 (

Indexed as

ParechovirusPhylogenyAlbertaCentral Nervous System InfectionsCommunicable Diseases, EmergingFemaleGenome, ViralHumansInfantInfant, NewbornMalePicornaviridae InfectionsRetrospective Studiesencephalitishuman parechovirusmeningo-encephalitispediatricsrecombinantviral meningitis

Identifiers

PMID39599798
PMCPMC11599023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.